Status:
COMPLETED
Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Conditions:
Irritable Bowel Syndrome
Healthy Subjects
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Patients with disorders of gut-brain interaction (DGBI) often present gastrointestinal symptoms that do not show noticeable irregularities in standard examinations. However, due to unclear causes and ...
Eligibility Criteria
Inclusion
- Inclusion criteria for healthy subjects:
- Age between 18 and 70, mentally alert and willing to sign the consent form for the study.
- No gastrointestinal symptoms or use of gastrointestinal medication.
- Inclusion criteria for Laryngopharyngeal reflux disease subjects:
- Age between 18 and 70, mentally alert and willing to sign the consent form for the study.
- Gastroesophageal reflux disease (GERD) is defined as the condition characterized by experiencing symptoms for at least three months (such as hoarseness, sensation of a foreign body in the throat, chronic cough, and frequent throat clearing) occurring at least once a week. Reflux Symptom Index (RSI) is a standardized questionnaire for evaluating laryngopharyngeal reflux. It consists of nine reflux-related symptoms, with severity scores ranging from 0 (no symptoms) to 5 (most severe). A total score exceeding 13 indicates the criteria for inclusion of a patient as having laryngopharyngeal reflux.
- dyspepsia subjects:
- Age between 18 and 70, mentally alert and willing to sign the consent form for the study.
- Those who meet the definition of functional dyspepsia (FD). (Functional dyspepsia is chronic ( once a week , lasting for at least three months, at least six months before the first symptom) upper gastrointestinal symptoms (any of the following ) : postprandial abdominal distension, easy feeling of fullness, upper abdominal pain Or upper abdominal burning sensation, and no symptoms of gastrointestinal bleeding or significant weight loss, no abnormality after upper gastrointestinal endoscopy).
- Inclusion criteria for subjects with irritable bowel disorder:
- Age between 18 and 70, mentally alert and willing to sign the consent form for the study.
- meet the definition of irritable bowel disorder (IBS) . Irritable bowel syndrome is chronic ( once a week , lasting for at least three months) lower gastrointestinal symptoms: abdominal pain combined with diarrhea or constipation , and no symptoms of gastrointestinal bleeding or significant weight loss, no abnormalities after colonoscopy) .
Exclusion
- Pregnant or lactating women.
- Infected with antibiotic resistance.
- Received endotracheal intubation in the past two months .
- Having myocardial ischemia or recently experienced a myocardial infarction.
- Unable to collaborate.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT06205446
Start Date
September 1 2023
End Date
December 31 2024
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hualien Tzu Chi Hospital
Hualien City, Taiwan, 970